- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 86,940 | 20.06.24 11:54:43 | -0,750 | -0,86% | 87,180 | 87,240 | 86,830 | 87,690 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 980,000 | 20.06.24 12:12:01 | +16,200 | +1,68% | 971,000 | 981,000 | 966,200 | 963,800 |
